Holen Sie sich die Stockscreener-App
34.59
4.12%
1.37
Handel nachbörslich:
34.59
Schlusskurs vom Vortag:
$33.22
Offen:
$33.55
24-Stunden-Volumen:
972.66K
Relative Volume:
2.64
Marktkapitalisierung:
$2.42B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-195.21M
KGV:
-10.89
EPS:
-3.1763
Netto-Cashflow:
$-176.19M
1W Leistung:
+0.03%
1M Leistung:
+11.26%
6M Leistung:
+38.14%
1J Leistung:
+92.17%
1-Tages-Spanne:
$33.16
$34.74
1-Wochen-Bereich:
$33.00
$34.98
52-Wochen-Spanne:
$17.62
$35.91
Pharvaris Nv Stock (PHVS) Company Profile
Compare PHVS vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
34.59 | 2.32B | 0 | -195.21M | -176.19M | -3.1763 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-09 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-10-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-10-09 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-06-11 | Eingeleitet | Guggenheim | Buy |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-09-25 | Eingeleitet | Wedbush | Outperform |
| 2023-08-15 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | Eingeleitet | Bryan Garnier | Buy |
| 2022-09-13 | Fortgesetzt | JMP Securities | Mkt Outperform |
| 2022-08-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-05-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-03-02 | Eingeleitet | BofA Securities | Neutral |
| 2021-03-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2021-03-02 | Eingeleitet | Oppenheimer | Outperform |
| 2021-03-02 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Pharvaris Nv Aktie (PHVS) Neueste Nachrichten
FDA accepts deucrictibant IR application for on-demand treatment of hereditary angioedema attacks - Contemporary Pediatrics
FDA accepts Pharvaris NDA for oral HAE attack treatment drug - Investing.com
Pharvaris wins FDA review for oral HAE attack treatment - Stock Titan
PHVSPharvaris NV Latest SEC Filings - Finviz
Pharvaris Insider Sold Shares Worth $1,331,496, According to a Recent SEC Filing - marketscreener.com
Pharvaris Insider Sold Shares Worth $2,695,452, According to a Recent SEC Filing - marketscreener.com
Insider Sell: Schikan Johannes Gerardus Christiaan Petrus Sells 37,600 Shares of Pharvaris NV (PHVS) - GuruFocus
Pharvaris (PHVS) director sells 37,600 shares in Rule 10b5-1 plan - Stock Titan
Pharvaris (PHVS) exec Lesage exercises options and sells 76K shares - Stock Titan
PHVS (NASDAQ) insiders executed multiple 10b5-1 sales in 2026 - Stock Titan
PHVS insiders (PHVS) list option exercise and multiple 10b5-1 sales in June 2026 - Stock Titan
Form 144: Hans H. Schikan 10b5-1 sales listed for PHVS (PHVS) - Stock Titan
Insider Sell: Schikan Johannes Gerardus Christiaan Petrus Sells Shares of Pharvaris NV (PHVS) - GuruFocus
Form 144 Pharvaris N.V. For: 29 June By Investing.com - Investing.com South Africa
Pharvaris (PHVS) exec’s 10b5-1 option exercise and 4,600-share sale - Stock Titan
Pharvaris (PHVS) director’s 2,400-share Rule 10b5-1 stock sale detailed - Stock Titan
Pharvaris (PHVS) CMO Lu Peng exercises options, sells 29,700 shares under 10b5-1 plan - Stock Titan
PHVS (NASDAQ: PHVS) 10b5-1 sales logged; Form 144 for 6,888 shares - Stock Titan
PHVS holders execute multiple 10b5-1 sales (NASDAQ: PHVS) - Stock Titan
8,300-share option exercise; multiple 10b5-1 sales reported (PHVS) - Stock Titan
Price to book forward of Pharvaris N.V. – GETTEX:9EN - TradingView
Liquidity Mapping Around (PHVS) Price Events - Stock Traders Daily
PHVS Gains 2.13% as Biotech Sentiment Brightens – Key Levels to WatchValue Factor - dars.gov.et
Price to book forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView
Enterprise value to revenue forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView
Pharvaris N.V. Actuals & Estimates (NASDAQ:PHVS) - TradingView
Enterprise value to revenue forward of Pharvaris N.V. – LS:A2QNWS - TradingView
Price to sales forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView
Price to book forward of Pharvaris N.V. – LS:A2QNWS - TradingView
Enterprise value to EBITDA forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView
Price to earnings forward of Pharvaris N.V. – LS:A2QNWS - TradingView
[144] Pharvaris N.V. SEC Filing - Stock Titan
Enterprise value to EBIT forward of Pharvaris N.V. – NASDAQ:PHVS - TradingView
Pharvaris Shareholders Approve 2025 Accounts and Renew Board Authorities at 2026 AGM - TipRanks
[6-K] Pharvaris N.V. Current Report (Foreign Issuer) | PHVS SEC FilingForm 6-K - Stock Titan
PHVS Forecast — Price Target — Prediction for 2027 - TradingView
Pharvaris N.V. Actuals & Estimates (FWB:9EN) - TradingView
Form 144 Pharvaris N.V. For: 25 June By Investing.com - Investing.com India
9EN Forecast — Price Target — Prediction for 2027 - TradingView
PHVS (NASDAQ) director 10b5-1 sales include 29,070 shares on 04/30/2026 - Stock Titan
PHVS (NASDAQ: PHVS) insider plans to sell 15,000 shares after option exercise - Stock Titan
PHVS Maintained by Morgan Stanley -- Price Target Raised to $46. - GuruFocus
PHVS (NASDAQ) reports director/entity 10b5-1 sales on April 22–30, 2026 - Stock Titan
PHVS (NASDAQ) files Form 144: 2,300 shares tied to option exercise - Stock Titan
Robust RAPIDe-3 Deucrictibant Data Might Change The Case For Investing In Pharvaris (PHVS) - Sahm
Pharvaris (PHVS) CMO sells 300 shares in scheduled 10b5-1 trade - Stock Titan
Pharvaris (PHVS) Is Up 6.0% After Strong Phase 3 Oral HAE Data With Novel Endpoint Introduction - Sahm
PHVS Q1 2026 Earnings: Narrower-Than-Expected Loss Amid Clinical ProgressRevenue Miss Report - dars.gov.et
PHVS reports 10b5-1 sales and option exercise (PHVS) - Stock Titan
Pharvaris NV (PHVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pharvaris (PHVS) CEO Modig sells 2,291 shares in planned Rule 10b5-1 trades - Stock Titan
Finanzdaten der Pharvaris Nv-Aktie (PHVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Pharvaris Nv-Aktie (PHVS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Schikan Johannes Gerardus Chri | Director |
Jun 29 '26 |
Sale |
35.05 |
6,888 |
241,447 |
345,879 |
| Lesage Anne | Chief Early Development |
Jun 30 '26 |
Option Exercise |
7.47 |
27,872 |
208,142 |
86,622 |
| Lesage Anne | Chief Early Development |
Jun 29 '26 |
Option Exercise |
5.22 |
10,600 |
55,300 |
67,050 |
| Lesage Anne | Chief Early Development |
Jun 30 '26 |
Sale |
35.49 |
30,703 |
1,089,637 |
93,969 |
| Lesage Anne | Chief Early Development |
Jun 30 '26 |
Sale |
35.48 |
27,872 |
988,890 |
58,750 |
| Lesage Anne | Chief Early Development |
Jun 29 '26 |
Sale |
35.07 |
10,600 |
371,693 |
56,450 |
| Lesage Anne | Chief Early Development |
Jun 29 '26 |
Sale |
35.05 |
6,997 |
245,232 |
124,672 |
1.18%
2.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):